Drug Search Results
More Filters [+]

Terbogrel

Alternative Names: terbogrel
Latest Update: 2014-08-22
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: TXA2 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Terbogrel

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT02223494

P2

Terminated

Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary

2000-03-01

NCT02223481

P2

Completed

Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary

1999-09-01

NCT02222987

P1

Completed

Healthy Volunteers

1999-03-01

Recent News Events

Date

Type

Title